March Bio Starts Phase 2 Trial for Rare Blood Cancer
March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma.
The test will take place at leading cancer centers across the country, with the first patient dosed at The University of Texas MD Anderson Cancer Center, the company stated.
The MB-105 program was granted FDA orphan drug designation in January 2025 and is also in development for other CD5+ cancers, it said.
'This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,' said Sarah Hein, March Biosciences co-founder and CEO.
Contact:
Exec Edge
Editor@executives-edge.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease
NORFOLK, Va.--(BUSINESS WIRE)-- ReAlta Life Sciences, Inc. ('ReAlta' or the 'Company'), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (pegtarazimod) for the treatment of Graft-versus-Host Disease (GvHD). The Orphan Drug Designation was supported by preliminary data from ReAlta's ongoing Phase 2 trial, which included data from the initial cohort of steroid-refractory Acute GvHD (aGvHD) patients. ReAlta is currently enrolling the Phase 2, open-label clinical trial of pegtarazimod for hospitalized patients with steroid-refractory aGvHD (NCT06343792) at clinical sites in the United States, Germany, and Spain. The Company expects to report data from additional cohorts of patients enrolled in this trial in 2026. In August 2024, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to pegtarazimod for the treatment of aGvHD. 'Receiving EMA Orphan Drug Designation represents a significant new regulatory milestone in our efforts to address the urgent unmet need in aGvHD, and we are particularly encouraged by the EMA's positive feedback to our initial cohort of Phase 2 data,' said David Marek, Chief Executive Officer of ReAlta. 'This designation, alongside our existing FDA Orphan Drug and Fast Track Designations for aGvHD, validates the potential of our novel dual-targeting approach to modulate both neutrophil and complement-mediated inflammation as we advance our Phase 2 trial to bring this potential therapy to aGvHD patients in Europe.' Kenji Cunnion, MD, MPH, Chief Medical Officer of ReAlta, commented, 'Our targeted intervention addresses the specific pathways driving tissue damage, including the inhibition of extracellular myeloperoxidase, NETosis and neutrophil elastase, while preserving beneficial immune function, unlike broadly immunosuppressive approaches to treat aGvHD. The compelling preclinical and clinical data that we have generated shows pegtarazimod's potential to address the neutrophil-driven disease process in patients with lower gastrointestinal (GI) aGvHD that is the most difficult to treat and has the highest rate of mortality.' The EMA grants Orphan Drug Designation to medicines intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. This designation provides pharmaceutical companies with certain benefits including reduced regulatory fees, clinical protocol assistance, and up to 10 years of market exclusivity in the European Union, if approved. About the Phase 2 aGvHD Trial and RLS-0071 (pegtarazimod) The Phase 2 trial (NCT06343792) is an open-label, prospective, dose-escalation trial currently enrolling patients across clinical sites in the United States, Germany, and Spain, evaluating pegtarazimod in hospitalized patients with moderate to very severe steroid-refractory acute graft-versus-host disease. Pegtarazimod is a 15-amino-acid peptide that uniquely targets both humoral and cellular inflammation and is the Company's lead therapeutic candidate. The peptide works by selectively inhibiting complement activation at C1, as well as myeloperoxidase (MPO) activity and neutrophil extracellular trap (NET) formation – key mechanisms that drive the inflammatory cascade and tissue damage when donor immune cells attack recipient tissues following hematopoietic stem cell transplantation. About ReAlta Life Sciences ReAlta Life Sciences, Inc. is a clinical mid-stage biopharmaceutical company dedicated to addressing life threatening rare and acute inflammatory diseases by rebalancing the inflammatory response. The Company's EPICC peptide platform leverages discoveries from the human astrovirus (HAstV-1), which uniquely inhibits components of the innate immune system. ReAlta's therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs). The Company's lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that causes brain damage and high mortality in oxygen-deprived newborns; FDA Orphan Drug and Fast Track Designations for acute graft-versus-host disease (aGvHD) associated with bone marrow and stem cell transplants; Orphan Drug Designation by the European Medicines Agency for both HIE and GvHD; and FDA IND clearance for acute exacerbations of chronic obstructive pulmonary disease (COPD). Founded in 2018, ReAlta operates in Norfolk, Virginia and Aguadilla, Puerto Rico. For more information, please visit
Yahoo
44 minutes ago
- Yahoo
Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment
Precigen, Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to buy according to analysts. On August 15, the stock exploded by more than 70% after the US Food and Drug Administration approved PAPZIMEOS for treating adults with recurrent respiratory papillomatosis (RRP). Elena Pavlovich/ The rally in the market came as the approval made PAPZIMEOS the first and only FDA-approved therapy for adult RRP patients. The FDA approved the treatment option without requiring Precigen to conduct a confirmatory clinical trial, despite the initial submission being made under an accelerated approval pathway. 'With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease,' said Helen Sabzevari, President and CEO of Precigen. Precigen has established Papzimeos SUPPORT, a patient support program offering services including insurance navigation and financial assistance. The program is part of the company's push to promote the newly FDA-approved treatment. Precigen, Inc. (NASDAQ:PGEN) is a biopharmaceutical company that focuses on developing and commercializing gene and cell therapies using precision medicine technologies. They are dedicated to addressing complex diseases in immuno-oncology, autoimmune disorders, and infectious diseases. While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Tech Stocks with Strong Return on Equity and 13 Best NYSE Penny Stocks to Invest in Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Newsweek
an hour ago
- Newsweek
Bread Recall Sparks Highest Consumer Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of numerous bread products over potential undeclared allergens has received the highest risk warning from the Food and Drug Administration (FDA). Hillside Orchard Farms Inc., based in Georgia, issued a voluntary recall for the products on July 22 because of the possible undeclared presence of eggs. The FDA issued a Class I risk classification for the recall on August 20. Newsweek contacted Hillside Orchard Farms Inc. for comment by phone outside regular working hours. Why It Matters Eggs are one of the nine major food allergens as defined in law. The others are fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, sesame and milk. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. A stock image of a bread product. A stock image of a bread product. Torsten Sukrow/picture-alliance/dpa/AP What To Know A Class I risk classification represents "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the FDA. The agency warned in its recall notice, "People who have an allergy or severe sensitivity to egg run the risk of serious or life-threatening allergic reaction if they consume these products." These are the products affected by the recall: Apple Bread—product number: 1001 Apple Fritters—product number: 1051 Banana Nut Bread—product number: 1016 Blackberry Bread—product number: 1014 Blueberry Bread—product number: 1013 Blueberry Fritters—product number: 1063 Cheese Bread—product number: 1017 Cinnamon Pecan Bread—product number: 1012 Cinnamon Pecan Fritters—product number: 1062 Jalapeño Cheese Bread—product number: 1018 Peach Bread—product number: 1002 Peach Fritters—product number: 1052 Strawberry Bread—product number: 1011 Strawberry Fritters—product number: 1061 The products had use-by dates through July 23 and were distributed between November 18, 2024, and July 16, 2025. The products were sold primarily in farm markets and on roadside stands in Alabama, Georgia, North Carolina, Pennsylvania and South Carolina. The company initiated the recall after an FDA investigation found that the product labels failed to include the allergen egg. As of July 28, no illnesses had been reported in connection with the consumption of the recalled products. What People Are Saying The FDA said on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recall is listed as ongoing, according to the FDA. Consumers who purchased the affected products are urged to return them to their place of purchase for a full refund.
